Management of renal bone disease

被引：0

作者：

Roberts, Darren M. ^{[1
]}

Singer, Richard F. ^{[1
]}

机构：

[1] Canberra Hosp, Dept Renal Med, Canberra, ACT, Australia

来源：

AUSTRALIAN PRESCRIBER | 2010年 / 33卷 / 02期

关键词：

kidney disease; parathyroid hormone; phosphate binders; vitamin D; DIALYSIS OUTCOMES; PRACTICE PATTERNS; MINERAL METABOLISM; HEMODIALYSIS; MORTALITY; RISK;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Renal bone disease occurs in patients with chronic kidney disease. There are changes in the concentrations of calcium, phosphate, vitamin D and parathyroid hormone. Systemic complications include renal osteodystrophy and soft tissue calcification, which contribute to morbidity and mortality. As the changes of renal bone disease are potentially modifiable, early referral to a nephrologist for monitoring and treatment is recommended. Early advice about diet and regular monitoring of calcium, phosphate and parathyroid hormone are necessary. Careful prescribing of drugs and dialysis to achieve specific biochemical targets can minimise the complications. Phosphate binders and vitamin D analogues are required by most patients with advanced renal failure.

引用

页码：34 / 37

页数：4

共 50 条

[41] Incidence, management, and outcomes of end-stage renal disease in the elderly
Tamura, Manjula Kurella
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2009, 18 (03) : 252 - 257
[42] Bone mineral metabolism in patients with chronic kidney disease on dialysis in Southern Metropolitan Santiago
Ruiz de Arechavaleta, Andrea
Quintero, Nerio
Daniela Parra, E. U.
Jara, Aquiles
Russo, Moises
Zitko, Pedro
Pefaur, Jacqueline
REVISTA MEDICA DE CHILE, 2015, 143 (02) : 168 - 174
[43] CHRONIC KIDNEY DISEASE-MINERAL BONE DISORDER IN THE ELDERLY PERITONEAL DIALYSIS PATIENT
Heaf, James Goya
PERITONEAL DIALYSIS INTERNATIONAL, 2015, 35 (06): : 640 - 644
[44] Mineral and bone disorder biomarkers and inflammation indexes in patients with end stage renal disease
Zhang, Lu
Yu, Qingtan
Chen, Xing
Zhang, Mengqin
He, Yan
Ji, Zhiqian
Chen, Rongjuan
Zhang, Jun
Zhang, Hengyuan
Shi, Guixiu
Huang, Jiyi
ANNALS OF PALLIATIVE MEDICINE, 2020, 9 (06) : 3938 - 3946
[45] Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease
Cernaro, Valeria
Calimeri, Sebastiano
Laudani, Alfredo
Santoro, Domenico
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2020, 16 : 871 - 880
[46] Use of Vitamin D Receptor Activator, Incident Cardiovascular Disease and Death in a Cohort of Hemodialysis Patients
Shoji, Tetsuo
Marubayashi, Seiji
Shigematsu, Takashi
Iseki, Kunitoshi
Tsubakihara, Yoshiharu
THERAPEUTIC APHERESIS AND DIALYSIS, 2015, 19 (03) : 235 - 244
[47] Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients
Kalantar-Zadeh, K.
Kuwae, N.
Regidor, D. L.
Kovesdy, C. P.
Kilpatrick, R. D.
Shinaberger, C. S.
McAllister, C. J.
Budoff, M. J.
Salusky, I. B.
Kopple, J. D.
KIDNEY INTERNATIONAL, 2006, 70 (04) : 771 - 780
[48] Organic and Inorganic Dietary Phosphorus and Its Management in Chronic Kidney Disease
Noori, Nazanin
Sims, John J.
Kopple, Joel D.
Shah, Anuja
Colman, Sara
Shinaberger, Christian S.
Bross, Rachelle
Mehrotra, Rajnish
Kovesdy, Csaba P.
Kalantar-Zadeh, Kamyar
IRANIAN JOURNAL OF KIDNEY DISEASES, 2010, 4 (02) : 89 - 100
[49] Analysis of renal bone disease treatment in dialysis patients
Johnson, CA
McCarthy, J
Bailie, GR
Deane, J
Smith, S
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (06) : 1270 - 1277
[50] Bone loss after renal transplantation: role of hyperparathyroidism, acidosis, cyclosporine and systemic disease
Heaf, J
Tvedegaard, E
Kanstrup, IL
Fogh-Andersen, N
CLINICAL TRANSPLANTATION, 2000, 14 (05) : 457 - 463

← 1 2 3 4 5 →